deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT01640782

Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach (ITACA-S)

Open Label, Randomised, Multicenter Phase III Study of Adjuvant Chemotherapy in Radically Resected Adenocarcinoma of the Stomach or Gastroesophageal Junction: Comparison of a Sequential Treatment (CPT-11+5-FU/LV --> TXT+CDDP) Versus a 5-FU/LV Regimen

Sponsor: Aventis Pharmaceuticals

Updated 7 times since 2017 Last updated: Jul 17, 2014 Started: Feb 28, 2005 Primary completion: Jan 31, 2013 Completion: Jan 31, 2013
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Adenocarcinoma of the Gastroesophageal Junction and Adenocarcinoma of the Stomach, this trial is completed. The trial is conducted by Aventis Pharmaceuticals and has accumulated 7 data snapshots since 2005. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Apr 2025 · 7 months · monthly snapshotCompleted~Apr 2025 – ~Sep 2025 · 5 months · monthly snapshotCompleted~Sep 2025 – present · 10 months · monthly snapshotCompleted

Change History

7 versions recorded
  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Apr 2025 — Sep 2025 [monthly]

    Completed PHASE3

  3. Sep 2024 — Apr 2025 [monthly]

    Completed PHASE3

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  5. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

Show 2 earlier versions
  1. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  2. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Feb 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Aventis Pharmaceuticals
  • Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
  • Gruppo Oncologico Italiano di Ricerca Clinica
  • Gruppo Oncologico del Nord-Ovest
  • Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
  • Italian Trial in Medical Oncology
  • Mario Negri Institute for Pharmacological Research
  • Oncotech
  • Southern Italy Cooperative Oncology Group
Data source: Mario Negri Institute for Pharmacological Research

For direct contact, visit the study record on ClinicalTrials.gov .